Dr. Neal Shore on the future of darolutamide in prostate cancer

March 1, 2021
Urology Times staff

Darolutamide is currently approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Neal D. Shore, MD, medical director of the Carolina Urologic Research Center, highlights the next steps for darolutamide (Nubeqa) in prostate cancer. The FDA approved the androgen receptor pathway inhibitor in July 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer, based on findings from the phase 3 ARAMIS trial.